PeptideVS
Growth Hormone
Not submitted
Evidence: Emerging

Ipamorelin

Also known as: NNC 26-0161

Overview
Growth hormone optimization

Ipamorelin is a pentapeptide that selectively stimulates growth hormone release by mimicking ghrelin, the hunger hormone. Unlike many other GH secretagogues, ipamorelin does not significantly increase cortisol or prolactin levels, making it a "cleaner" option with fewer side effects. It is commonly stacked with CJC-1295 for synergistic effects on GH production.

Mechanism of Action

Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH release without affecting cortisol or prolactin

Dosage Information
ParameterDetail
AdministrationSubcutaneous injection
Typical Dose200-300mcg 2-3x daily
FrequencyDaily
Side Effects
Reported adverse effects from clinical data and post-market surveillance

Common Side Effects

Injection site reactions
Increased hunger
Headache
Mild water retention

Serious Side Effects

Potential insulin resistance
Unknown long-term effects
!Contraindications
Do not use this peptide if any of the following apply
  • Active cancer
  • Pregnancy
  • Children
Clinical Evidence

Evidence Quality

Emerging

Clinical Trial Phase

Preclinical / Not submitted

View Key Study
Cost Comparison
Estimated monthly costs compared to similar peptides
PeptideMonthly CostFDA Status
Ipamorelin$35 - $70/mo
Not submitted
MK-677$50 - $100/mo
Phase 2
CJC-1295$35 - $70/mo
Not submitted
GHRP-6$35 - $70/mo
Not submitted
Sermorelin$150 - $350/mo
FDA Approved
Compare Ipamorelin
See how Ipamorelin stacks up against similar peptides
Ipamorelin vs CJC-1295Ipamorelin vs MK-677

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.